Published in AIDS Weekly, October 18th, 1999
When given together with highly active antiretroviral therapy (HAART), daily subcutaneous (SQ) IL-2 boosts T-cell and natural-killer (NK) cell counts, a new study confirms. Even more exciting are data suggesting that IL-2 given in this context can restore lost immunity to HIV to the degree that a patient could stop taking HAART and avoid the drugs' side effects.
E.L. Jacobson and colleagues of Cornell University, New York, set up a protocol in which patients added SQ IL-2 to their HAART regimens. Some of the patients are scheduled to stop taking HAART when their T-cell...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.